Literature DB >> 19372260

A novel deletion mutation is recurrent in von Willebrand disease types 1 and 3.

Megan S Sutherland1, Anthony M Cumming, Mackenzie Bowman, Paula H B Bolton-Maggs, Derrick J Bowen, Peter W Collins, Charles R M Hay, Andrew M Will, Stephen Keeney.   

Abstract

Direct sequencing of VWF genomic DNA in 21 patients with type 3 von Willebrand disease (VWD) failed to reveal a causative homozygous or compound heterozygous VWF genotype in 5 cases. Subsequent analysis of VWF mRNA led to the discovery of a deletion (c.221-977_532 + 7059del [p.Asp75_Gly178del]) of VWF in 7 of 12 white type 3 VWD patients from 6 unrelated families. This deletion of VWF exons 4 and 5 was absent in 9 patients of Asian origin. We developed a genomic DNA-based assay for the deletion, which also revealed its presence in 2 of 34 type 1 VWD families, segregating with VWD in an autosomal dominant fashion. The deletion was associated with a specific VWF haplotype, indicating a possible founder origin. Expression studies indicated markedly decreased secretion and defective multimerization of the mutant VWF protein. Further studies have found the mutation in additional type 1 VWD patients and in a family expressing both type 3 and type 1 VWD. The c.221-977_532 + 7059del mutation represents a previously unreported cause of both types 1 and 3 VWD. Screening for this mutation in other type 1 and type 3 VWD patient populations is required to elucidate further its overall contribution to VWD arising from quantitative deficiencies of VWF.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19372260     DOI: 10.1182/blood-2008-08-173278

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

1.  Characterization of large in-frame von Willebrand factor deletions highlights differing pathogenic mechanisms.

Authors:  Ashley Cartwright; Simon J Webster; Annika de Jong; Richard J Dirven; Lisa D S Bloomer; Ahlam M Al-Buhairan; Ulrich Budde; Christer Halldén; David Habart; Jenny Goudemand; Ian R Peake; Jeroen C J Eikenboom; Anne C Goodeve; Daniel J Hampshire
Journal:  Blood Adv       Date:  2020-07-14

2.  The molecular basis of von Willebrand disease: the under investigated, the unexpected and the overlooked.

Authors:  Daniel J Hampshire; Anne C Goodeve
Journal:  Haematologica       Date:  2011-06       Impact factor: 9.941

3.  The role of genetics in the pathogenesis and diagnosis of type 1 Von Willebrand disease.

Authors:  Veronica H Flood; Jessica Garcia; Sandra L Haberichter
Journal:  Curr Opin Hematol       Date:  2019-09       Impact factor: 3.284

Review 4.  von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studies.

Authors:  Paula D James; David Lillicrap
Journal:  Am J Hematol       Date:  2012-03-03       Impact factor: 10.047

5.  In silico analysis highlights the copy number variation mechanism responsible for the historically reported VWF exon 42 deletion.

Authors:  A Cartwright; I R Peake; A C Goodeve; D J Hampshire
Journal:  Haemophilia       Date:  2016-08-01       Impact factor: 4.287

Review 6.  Perils, problems, and progress in laboratory diagnosis of von Willebrand disease.

Authors:  Veronica H Flood
Journal:  Semin Thromb Hemost       Date:  2013-12-12       Impact factor: 4.180

Review 7.  New insights into genotype and phenotype of VWD.

Authors:  Veronica H Flood
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2014-11-18

8.  The genetics of Canadian type 3 von Willebrand disease: further evidence for co-dominant inheritance of mutant alleles.

Authors:  M Bowman; A Tuttle; C Notley; C Brown; S Tinlin; M Deforest; J Leggo; V S Blanchette; D Lillicrap; P James
Journal:  J Thromb Haemost       Date:  2013-03       Impact factor: 5.824

Review 9.  The molecular characterization of von Willebrand disease: good in parts.

Authors:  P D James; D Lillicrap
Journal:  Br J Haematol       Date:  2013-02-14       Impact factor: 6.998

10.  Characterization of a Porcine Model for Von Willebrand Disease Type 1 and 3 Regarding Expression of Angiogenic Mediators in the Nonpregnant Female Reproductive Tract.

Authors:  Hanna Allerkamp; Stefanie Lehner; Mahnaz Ekhlasi-Hundrieser; Carsten Detering; Christiane Pfarrer; Mario von Depka Prondzinski
Journal:  Comp Med       Date:  2019-09-16       Impact factor: 0.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.